CATX: Perspective Therapeutics Inc Forward P/S Multiple

Corporate emblem and logo of Perspective Therapeutics, Inc. (CATX)

The forward price-to-sales multiple chart for Perspective Therapeutics (CATX) demonstrates a lack of current profitable products, as the development of Perspective Therapeutics (CATX) relies on investments in clinical trials. The 433.20 mark reflects the latest business valuation data. High brand authority in radiopharmaceuticals guarantees physician trust, while a scalable technological platform enables the creation of a series of high-margin drugs with minimal cost growth.

CATX Perspective Tx: Market Cap to Future Revenue Ratio in the range 06/21/2023 - 11/13/2026

Summary analytical data breakdowns for perspectivetherapeutics.com (CATX)

- stock price and consensus target price:
Stock Quotes Perspective Therapeutics, Inc.|CATX - Analyst Forecast Prices
- market capitalization information:
Market Capitalization CATX|CATX - Full Business Value
- issuer book value statistics:
Net Assets per Single Share Perspective Therapeutics|CATX - Total Stockholders' Equity|Market Value to Book Value Ratio perspectivetherapeutics.com|CATX - Aggregate Asset Value
- debt burden and liquidity indicators:
Debt to Equity Perspective Therapeutics|CATX - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Perspective Therapeutics, Inc.|CATX - Company Total Debt Obligations|Debt to Book Capitalization Ratio CATX|CATX - Long-Term Liabilities|Company Short-Term Debts Perspective Therapeutics|Quick Liquidity perspectivetherapeutics.com
- business earnings and investment ratios data:
CATX - Final Profit|Expected Profit Perspective Therapeutics|CATX - Business Payback Period|Future Price to Earnings Perspective Therapeutics, Inc.|CATX - Market Cap to Earnings and Growth Ratio|EV/EBITDA Multiple CATX|CATX - Profit before interest, taxes and amortization|Net earnings per share (EPS TTM) Perspective Therapeutics|CATX - Net earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months perspectivetherapeutics.com|CATX - Net earnings per one share growth for the current year|Earnings growth forecast for next year Perspective Therapeutics
- revenue and sales details:
CATX - Company Gross Revenue|Company Future Sales Volume Perspective Therapeutics, Inc.|CATX - Price-to-Revenue Ratio|Forward P/S Multiple CATX
Comprehensive company analysis:CATX (Perspective Therapeutics Inc)
Original product of Perspective Therapeutics, Inc.

The market evaluates the potential of Perspective Therapeutics (CATX) through the lens of its radiopharmaceutical partnerships for cancer therapy, pricing in future commercial success. An analysis of the forward P/S ratio allows for a comparison of current market capitalization against expected revenue, identifying whether the asset is overvalued or undervalued, which is critical for determining investment stability amid macroeconomic volatility.

Direct competitors

Geron - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio NBTX (Nanobiotix SA)|Bicycle Pharma - Forward P/S Multiple|Future Price to Revenue CTMX|genelux.com (GNLX) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio molecularpartners.com (MOLN)|Price-to-Projected Revenue Ratio Oncolytics Biotech, Inc.|LSTA: Forward Price to Sales|Price-to-Projected Revenue Ratio Moleculin Biotech, Inc. (MBRX)|Forward Price-to-Revenue Multiple galeratx.com GRTX|Price-to-Projected Revenue Ratio Molecular Templates MTEM